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This paper describes the treatment of Burkitt lymphoma (BL) from the time of its discovery in Africa up to the present. Pioneer
investigators explored the value of chemotherapy since surgery and radiation were not eﬀective modalities. Complete response
was observed with many drugs used as single agents, but Ziegler and colleagues showed that patients resistant to one drug could
achieve cure and potentially long-term survival with other drugs. Subsequently, a combination of cyclophosphamide (CTX),
vincristine(VCR),andmethotrexate(MTX)wasshowntobeactive,butasurvivaladvantagecomparedtoCTXalonecouldnotbe
demonstrated because eﬀective CNS prophylactic therapy, in the form of intrathecal therapy, was not given. A recent re-evaluation
of this regimen in Africa with multiple doses of intrathecal therapy compares favourably with recent studies of single agent CTX,
and other drugs have been shown to be non-cross resistant. Optimal results for patients with extensive disease probably require 5
or 6 eﬀective drugs along with intrathecal therapy, using MTX and Ara-C. In Africa, doses must be lower, because of limitations
in supportive care, but in technically advanced countries cure rates in excess of 90% can be obtained. Rituximab may improve the
results in some patient groups and allow less intensive therapy without a reduction in survival in others.
1.Introduction
Burkitt lymphoma (BL), in spite of its low incidence
throughout most of the world, has had a major impact
upon the understanding and treatment of lymphomas and
doubtless upon many other cancers. The fact that it was
discovered in equatorial Africa and much of the groundwork
fortheevolutionofitstreatmentwasconductedinequatorial
Africa in the 1960s and 70s, but little since, is an indication
of the great loss to research that results from the enormous
diﬀerences in resources that exist among the world’s coun-
tries. The rich variety of lifestyles, diets, and environmental
exposures in the world have probably never been greater, yet
the vast bulk of research is conducted in the high income
countries and in particular the OECD countries. Much of
this research is not relevant, at least, in the immediate
future, to the low- and many middle-income countries,
which have not yet built strong enough infrastructures to
carry out their own scientiﬁc investigations. Moreover, in the
realm of treatment, regimens have constantly increased in
complexity and cost with often questionable advantage, cer-
tainly when seen from the perspective of population med-
icine. Classiﬁcation and staging systems become more and
more complex such that diagnosis and staging comprise
signiﬁcant elements of the cost of managing a patient, with-
out necessarily resulting in improved survival. In the case of
Burkitt lymphoma, Burkitt himself showed many years ago
that a small fraction of patients could be cured with a sin-
gle dose of chemotherapy and that the extent of disease
was perhaps the most important determinant of outcome,
yet while patients with limited disease do receive limited
treatment, much of the more recent research into the treat-
ment of patients with extensive disease has been focused
on determining which elements of very intensive, albeit
successful therapies devised in recent years, can be removed2 Advances in Hematology
with impunity. Such studies have revealed a number of su-
perﬂuous elements, indicating that the ﬁrst highly successful
therapies were also excessively and, doubtless, therefore,
more toxic and more expensive. This is a very diﬀerent ap-
proachfromthattakenbypioneerchemotherapistsinAfrica,
where it was felt that the host response provided an impor-
tant part of therapy, and too much chemotherapy could, by
abrogating immunological defences against the tumor, lead
to a negative result. Unfortunately, this approach often led
to patients being undertreated, and since every patient is
diﬀerent,preciselyhowintensivethemanagementofpatients
needstobeisnoteasytodetermine.Nonetheless,today,most
patients with BL can be cured with intensive conventional
chemotherapy by accepting the fact that some will be over-
treated,butdirectingresearchtowardstryingtoidentifysuch
patients and minimizing therapy to the extent possible. This
approach has led to approximately 90% of children, and a
somewhat lower percentage of adults, being cured of their
disease.
With the advent of highly active antiretroviral therapy,
it has proved possible to use intensive therapy in AIDS pa-
tients, with a similar outcome to that achieved in non-
AIDS patients. In Africa, there should be little diﬃculty in
achieving reasonable survival rates in AIDS-related BL as
long as patients also receive HAART, although the disease
burden is likely to remain an important determinant of
outcome.
2. Discovery of the Tumor and Early
Therapeutic Studies
Dennis Burkitt was a surgeon who had been practicing at
the Mulago Hospital in Kampala, Uganda for almost ten
years before he saw his ﬁrst case of the lymphoma which
subsequently bore his name. Burkitt had reported a clinical
syndrome of jaw tumors with or without tumor at other sites
(particularly the abdomen) in 1958 [1]. Shortly afterwards,
O’Conor and Davis published a review of childhood cancer
in Uganda in which they reported that approximately 50%
of all malignant diseases in children had similar pathology
with clinical features consistent with those reported by
Burkitt, although not all had jaw tumors. They identiﬁed
the disease as a poorly diﬀerentiated lymphocytic lymphoma
[2]. Surgery had little to oﬀer these children, and radiation
therapy was not then available in equatorial Africa, but, in
1960, David Burchenal, who had been using methotrexate
(MTX) in patients with leukemia at the Sloane Kettering
Institute in New York, visited Mulago Hospital, bringing
some of the drug with him. Burkitt was persuaded to
try the drug in two children. Both had remarkably rapid
responses after a single dose of MTX, and although the ﬁrst
child subsequently relapsed, the second had a prolonged
remission. In the pioneering days of chemotherapy, when
many skeptics viewed cytotoxic therapy as merely a means of
delaying the inevitable, this was a critically important result
and triggered a great deal of interest in further treatment
studies. In the course of the next several years, Burkitt in
Uganda, Cliﬀord and Oettgen in Kenya, and Ngu in Nigeria,
assisted by collaborators in the USA and UK and drug
Table 1
Drug No. of
patients CR CR + PR %OR
Cyclophosphamide 163 43 132 81
Orthomerphalan 14 UK 14 100
Chlorambucil 12 3 10 83
N i t r o g e n m u s t a r d 6 1 1 04 47 2
Melphalan 26 8 16 61
Procarbazine 6 0 0 0
BCNU 5 0 4 80
Vincristine 21 10 17 81
Vinblastine 2 0 0 0
Methotrexate 45 11 26 58
6-Mercaptopurine 3 0 0 0
Cytosine arabinoside 3 2 2 2
Epipodophyllotoxin 2 2 2 2
Actinomycin D 4 1 4 4
CR: complete response; PR: partial respo2nse; OR: overall response.
Various doses and schedules were used, even for the same drug.
Adapted slightly from [12], UK = unknown.
donations, examined responses to many of the drugs then
available (Table 1)[ 3–7]. This was a less than systematic
process, and the drugs were used in various doses, schedules,
and even routes of administration, but given the absence of
any prior data on treatment response, the demonstration of
clear diminution in tumor size, complete clinical remission,
and over time, prolonged survival, even, on occasion,
with single doses of drug, clearly demonstrated the high
degree of chemosensitivity of the African lymphoma [8–
11], particularly, but not exclusively, to cyclophosphamide
(CTX), methotrexate (MTX), and vincristine (VCR) [3–8].
Anthracyclines (initially daunomycin) were not developed
untilthesecondhalfofthe1960ssowerenotassessedinthese
early studies. Indeed, single agent data is not available for the
anthracyclines although they were informally given to some
patients who relapsed (daunomycin or hydroxydaunomycin)
with minimal responses being seen, such that these drugs
were not further pursued at that time. Interestingly, in
contrast to the approach to acute lymphoblastic leukemia in,
for example, the USA, and related to both the extraordinarily
rapid response to therapy and diﬃculty for African patients
to stay at or near the hospital for prolonged periods, most
patients were treated with only one or two doses of the drug
beingtested—inretrospect,suﬃcienttocureonlyarelatively
small fraction of patients, mostly with limited disease.
In Burkitt’s series of 90 jaw tumors treated at the Mulago
Hospital Uganda with CTX, MTX, or VCR [9], 82% had
complete (CR) or partial responses (PR), those with small
tumors being much more likely (10 of 10) that those with
large tumors (10 of 40) to achieve a CR, suggesting a re-
lationship between response and tumor size, which was
subsequently conﬁrmed [10, 11]. Indeed, it seems likely that
theextentoftumoristhesinglemostimportantdeterminant
of treatment outcome, since even patients with central
nervous system disease (CNS) can be cured, particularlyAdvances in Hematology 3
when the total tumor burden is small—a situation relatively
common in Africa, where many patients with CNS disease
haveeitherajawororbitaltumor,orasmallextraduralmass,
all of which create major symptomatology and therefore
early diagnosis—but rare elsewhere, where CNS disease is
usually associated with extensive disease, particularly bone
marrow involvement. Burkitt also pointed out that complete
remissions occur within a few weeks or not at all and that
relapse is very uncommon after a year of remission. Such
“very late” relapses may, in fact, be second, clonally discrete
tumors occurring in patients at very high risk for BL [13].
LongerfollowupinUgandasuggestedthatapproximately
20% of patients could be expected to achieve long duration
remissions after (by today’s standards) minimal therapy
[14–16], and Burkitt noted that recurrence could occur at
previously uninvolved sites, a ﬁnding later conﬁrmed and
expandedbyZiegler,whoreportedthatearlyrelapses(within
1 0w e e k so fﬁ r s tt r e a t m e n t )w e r em o r el i k e l yt or e c u ra tt h e
original site of disease and/or in the central nervous system
(CNS), while those with late relapse (after 10 weeks, and
with a median remission duration of 26 weeks) were more
likely to relapse at previously uninvolved sites of disease and
only rarely in the CNS. The latter patients were also much
more sensitive to further chemotherapy than the former
[17, 18]. Burkitt noted that, in 12 patients known to have
died after a complete or almost complete remission, 6 were
duetoCNSlesions—atthattime,nopreventativeintrathecal
chemotherapy was given to any of the patients.
Ngu at the University College Hospital in Ibadan, Ni-
geria, and Cliﬀord, at the Kenyatta Hospital, in Nairobi,
also reported dramatic responses and long-term survivors
after treatment with CTX as well as, in Cliﬀord’s hands,
melphalan or orthomelphalan [4, 7, 8, 15], although patients
with extensive disease rarely achieved long-term survival.
Ngu brought attention to the fact that serum uric acid levels
were often raised in patients with extensive tumors and
sometimes became even more elevated following therapy, in
which case oliguric renal failure and death from electrolyte
disturbancesweretheresult.Thus,Nguappearstobetheﬁrst
to describe what would now be called the acute tumor lysis
syndrome(serumuricacidonthedayofdeathwas54mgper
100mL) and reported that this and other complications such
asperforationofthebowelmayensuefromrapiddissolution
of tumor following therapy. Knowledge of the severe conse-
quences of untreated massive tumor lysis syndrome led to
approaches to its management—initially massive hydration
with allopurinol to ensure that the tumor-derived uric acid
load was excreted. Alkalinization can be used during this
phase, since uric acid is more soluble in an alkaline urine.
But care should be taken not to “overshoot” since once the
uric acid level is suﬃciently low, the major problem becomes
excretion of phosphate, which is less soluble in an alkaline
urine and if insuﬃcient ﬂuids are given will precipitate in
the renal tubules, causing obstructive, oliguric renal failure
which is rapidly fatal in the absence of hemodialysis or
ﬁltration, which was not then, and is rarely now, available in
most hospitals in low income countries. Thus, the key to the
management of tumor lysis syndrome in patients with high
tumor burdens is hyperhydration, allopurinol, to decrease
uric acid formation and allow more oxypurine to e excreted
asxanthineandhypoxanthinewithcarefulobservationofthe
patient to ensure that a good urine ﬂow is sustained.
At this time, the relationship between BL and acute lym-
phoblastic leukemia, a rare disease in equatorial Africa, was
frequently debated [19]. Clift et al. described a group of 4
children with cytologically typical BL who had a leukemic
blood picture and/or diﬀuse bone marrow involvement at
either relapse or presentation [20] as rarities—overt leuke-
mia was rarely seen in African patients and although bone
marrow examinations were infrequently performed in life,
bone marrow involvement was present in less than 10% of
children who died from BL [21, 22]. Figures on incidence of
acute lymphoblastic leukemia (ALL) remain imprecise, but
it does seem to be becoming more frequent, as one would
expect, particularly in urban regions. Two of the children
reported by Clift were initially treated with prednisone
(40mgsperday)andmercaptopurine,thenstandardtherapy
for acute lymphoblastic leukemia (ALL). Neither responded
but one of the children was subsequently treated with
nitrogen mustard and there was marked, although tempo-
rary, tumor regression [19]. Many years later, a comparison
in children of ALL-like therapy versus repeated courses
of a drug combination including CTX, MTX, VCR, and
prednisone,carriedoutintheUSA,showedaclearadvantage
of the latter regime in patients with BL [23], although the
roleofprednisoneisunknown[20].Similarly,anthracyclines
have not been tested as single agents in ﬁrst-line therapy of
BL, but are included in most treatment regimens because of
their successful introduction into the therapy of lymphomas
in adults. It remains possible that they add little but toxicity
to treatment regimens for BL.
2.1. Non-Cross-Resistant Drugs. In the late 1960s and early
1970s, a collaboration between the Uganda Cancer Institute
(UCI) of Makerere University in Kampala and the National
Cancer Institute (NCI) of the USA resulted in several other
important observations. Of particular importance were the
demonstrations that CTX, VCR, and MTX were in large
part non-cross-resistant. Comparison of a single dose of
CTX with 6 doses (patients who achieved CR after one
dose being randomized to no more CTX or 5 more doses)
[10] showed that, among stage III patients treated with a
single dose of CTX, relapses occurred in the same site as the
original tumor, sometimes with concomitant CNS disease
and nearly always within 2 to 8 weeks of randomization.
Such patients responded to further CTX, 7 of 7 achieving a
second CR, indicating that a single dose of CTX represented,
for the vast majority of patients, inadequate therapy. Stage
III patients randomized to receive multiple doses of CTX
tended to relapse after 3–5 doses of CTX and all failed to
respond to additional CTX. Ten of the total of 24 patients
who relapsed after a CR following single-agent CTX, either
duringorshortlyafterthecompletionoftherapyweretreated
with a combination of VCR and MTX followed by Ara-C,
a regimen known as BIKE. Nine achieved a CR, 8 remaining
free of disease for 30–102 weeks (i.e., most were probably
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be likely to result in improved treatment outcome. This was
an important ﬁnding.
2.2. Early Drug Combinations. The eﬃcacy of combination
chemotherapy was tested in a second clinical trial conducted
at the LTC in which patients with stage III or IV disease,
who were randomized at the time of presentation to receive
either 6 doses of cyclophosphamide (40mgs/kg every 2-3
weeks—24 patients) or a sequential combination regimen
(TRIKE) consisting of CTX followed by VCR and MTX
followed by Ara-C (18 patients). These therapy components
were administered at approximately 2 weekly intervals until
2 cycles of TRIKE had been given [24]. Although the overall
relapse rate between the two arms of the study were quite
similar (with also no diﬀerence between stage III and IV
patients), there was a trend in favor of TRIKE. Patients
who received CTX alone invariably recurred at the same
anatomical location (often with CNS disease), and 7 of 8
who relapsed on treatment failed to respond to continuation
of CTX. In contrast, relapse in the TRIKE arm tended to
occur earlier, and, of 9 patients who relapsed on therapy,
6 responded to continuation of TRIKE (involving diﬀerent
agents), consistent with the notion that the drugs were non-
cross-resistant. Since at least some of the patients treated
in the CTX alone arm could be salvaged with BIKE and
because of the small numbers of patients available for
comparison, there appeared at ﬁrst to be no clear advantage
in terms of overall survival, although later followup did
indicate a survival advantage to patients initially treated with
TRIKE [25], again consistent with the value of combination
chemotherapy.
The early results achieved in the TRIKE trial suggested
that the use of a simultaneous drug combination from the
beginning would be advantageous. Accordingly, a random-
ized study was performed in which patients were initially
treated with CTX alone (2 doses 2 weeks apart) or with
two cycles of COM (a combination of CTX, VCR, and MTX
repeated after two weeks) [26]. Since an eﬀective means
of preventing CNS disease had still not been identiﬁed, no
IT therapy was given unless CNS disease was present (at
presentation or relapse). However, patients who achieved
remission were randomized to receive no further therapy
or craniospinal irradiation in Nairobi, where a radiation
therapy unit had recently been established. A dose of 20–
24Gy,in30fractionsovertwoweeks,wasgiven,butthisdose
failed to prevent CNS recurrence [27] and did not inﬂuence
the outcome of therapy. The proportion of relapses treated
with CTX alone or with COM was similar over the follow-up
period, but 7 of the 8 recurrences among 19 patients treated
with CTX alone involved both systemic and CNS disease,
while 8 of the 10 recurrences in the 21 patients who received
COM were conﬁned to the CNS. Later followup indicated
a survival advantage for patients treated with COM from
the outset [25], but the study also emphasized, once again,
the need for eﬀective prevention of CNS spread. Although
inadequate by modern standards, these data all pointed
towards combinations of drugs being more eﬀective, but, in
theabsenceofeﬀectiveCNStreatment,theiradvantagecould
not be realized.
In a similar time period, Nkrumah and Perkins, con-
ducted a series of studies in Accra, Ghana, initially support-
ing the conclusion that the BIKE regimen was non-cross-
resistant and also that simultaneous combination therapy
(in Ghana, a combination of CTX, Ara-C, and vincristine
was used, along with intrathecal methotrexate, during each
course of therapy) was likely to be more eﬀective [28, 29].
Very few patients developed CNS relapse compared to a
previous group of patients treated with CTX alone, and
the frequency of systemic relapse was also much lower in
patients randomized to combination therapy. Unfortunately,
the high toxic death rate in the latter arm prevented the
demonstration of a survival advantage. This study did
suggest,however,thatthereasonthatintrathecaltherapyhad
not been eﬀective previously is that it was not suﬃciently
prolonged—one cycle is not enough.
2.3. Prevention and Treatment of CNS Disease. Further con-
ﬁrmation of the need for multiple cycles of CNS therapy
had been suggested by early studies at the LTC in which IT
chemotherapy was given only to patients with overt CNS
disease. Various regimens, ranging from single weekly doses
to (remarkably) 10 consecutive days of therapy with either
methotrexate or Ara C, had been used but little success was
achieved. In contrast, a fraction of patients with CNS disease
at the time of relapse—for example, almost a third of those
with isolated CNS relapse—achieved long-term survival
when given multiple doses of IT therapy in conjunction
with additional systemic therapy. Moreover, some patients
with CNS recurrence after intrathecal methotrexate had
durable remissions when treated with multiple-dose IT Ara-
C[ 30], indicating the value of both drugs and suggesting
the need for more than a single course of therapy for
eﬀective CNS prophylaxis. Such a conclusion is taken as self-
evident today, although it did not seem obvious at that time.
Remarkably, however, (approximately 50%) of patients with
CNS disease occurring at any time in their disease achieved
prolonged survival following multiple doses of intrathecal
therapy, again, entirely consistent with the likelihood that
many patients were simply being inadequately treated with
intrathecal therapy.
Interestingly, unlike BL in the USA and Europe, a sig-
nificant fraction of patients presenting with CNS disease in
Africa have limited disease—for example, a jaw tumor or
isolated CNS relapse and many achieved prolonged survival,
although patients who had simultaneous CNS and systemic
relapse had a worse outcome [31]. This strongly suggested
that total tumor burden was more important than the mere
presence or absence of CNS disease in predicting outcome.
In contrast, patients in North America or Europe, where
CNS disease tends to occur in patients with systemically
advanced disease, particularly when there is bone marrow
involvement, have a poor prognosis—doubtless primarily
due to the overall disease burden, but interpreted for some
years as indicating that CNS disease per se was a poor prog-
nostic indicator—its presence is still suﬃcient to classify a
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2.4.TheRoleofOtherTherapeuticModalities. Chemotherapy
constitutes the primary therapy for BL. Surgery may have a
limited role in countries where suﬃciently intensive therapy
is not available—for example, when patients have access
only to CTX, but very few patients, apart from those in
rural Africa fall into this category. A retrospective study
conductedinUgandashowedasurvivaladvantagetopatients
in whom the bulk (estimated to be at least 90%) of all
abdominal tumor was resected prior to the commencement
of chemotherapy [33]. Surgery may be disadvantageous in
patients who are to receive high intensity therapy but, in
patients presenting with insussusception due to localized
small-volume bowel disease, total resection and limited
chemotherapy, without intrathecal therapy, results in an al-
most 100% survival rate.
Radiation therapy was also studied in Africa after radia-
tion became available in Nairobi. Single daily dose radiation
therapy was shown to be quite ineﬀective for the control
of local disease (with remission occurring in only 1 of 9
irradiated tumors), although hyperfractionation appeared
to be of some beneﬁt [34]. No new evidence contradicting
these data has been produced, either in Africa or elsewhere,
and radiation is not a component of standard therapy for
BL. These ﬁndings are very important to equatorial Africa,
for the rare need for surgery, and poor results of radiation
therapy indicate that this most common of pediatric cancers
requires little more than expert knowledge, a few drugs, and
a minimum of equipment for patients to be successfully
treated. This should not be interpreted to mean that patients
can be treated at any district hospital. It is essential that
the treating physician is familiar with the characteristics of
the disease, the side eﬀects, and the complications that can
arise from therapy and that there are adequate facilities for
hydration—and if necessary dialysis.
3. The Evolution of Therapy in the USA,
Europe and Adults
The COM regimen was adopted at the US National Cancer
Institute in the 1970s [35] and formed the backbone on
which modern intensive chemotherapy regimens used ﬁrstly
in children with BL and subsequently in adults [36–41]h a v e
been developed. The regimens have become increasingly
intensiveandhaveledtosurvivalratesofapproximately90%.
In fact, the primary goal of therapeutic studies today is to
deﬁneriskgroupsasaccuratelyaspossible,suchthatpatients
receive the minimum of therapy consistent with the best
possible outcome. Initially, these more intensive protocols
were more intensive than they needed to be, and it has
taken some years and a number of studies to demonstrate
this. It is even possible that anthracycline, added when this
drug was felt to be of major importance in the treatment of
adult non-Hodgkin’s lymphoma, adds nothing but toxicity
to childhood Burkitt lymphoma. Late cardiac toxicity occurs
at much lower cumulative doses than acute toxicity and is a
particular problem in children whose cardiac development
may be impaired and should, if at all possible, be avoided.
A randomized study is currently being conducted to explore
this. In addition, the advent of rituximab has led to the
possibility of obtaining the same excellent results with less
toxicity. Once again, this drug is being tested in children with
Burkitt lymphoma, although the excellent results achieved
with modern intensive chemotherapy mean that, initially,
subgroupsofpatientswithasomewhatworseprognosismust
be identiﬁed for clinical trials of the eﬃcacy of ritixumab,
o ru s em a d eo fp h a s eI Iw i n d o w s[ 42]. One such study
did show eﬃcacy of rituximab, and, in adults, where the
outcome of therapy has been generally somewhat worse than
in children, it has been simpler to add ritixumab to therapy
and demonstrate an advantage [43, 44].
The intensive treatment approaches used in the western
world are not suitable for use in equatorial Africa, where
facilities for supportive care remain extremely limited—
the paucity of appropriate treatment facilities coupled to
poverty have a marked impact on access to care. Recently,
therefore, several groups, including the International Soci-
ety of Pediatric Oncology, the Groupe Francophone pour
Oncologie Pediatrique, and the International Network for
CancerTreatmentandResearch,haveworkedwithcolleagues
in Africa and other low- and middle-income countries to
develop suitable protocols for African countries (including
North Africa, where facilities are better) [45–48].
3.1. Therapy of African Burkitt Lymphoma Today. An initial
study in Malawi with therapy based on the French LMB
studies but much less intensive, in which patients with St
Jude stage IV were excluded, showed that event-free survival
was 57% for all patients (10 stage I, 5 stage II, and 29
stage III) with a stable survival curve at 500 days [45].
Cyclophosphamide monotherapy was also retrospectively
utilized in Malawi in the late 1990s at a dose of 40mgs per
Kg every two weeks. Patients received between 1 and 12
doses [46]. Only 72 of 90 patients were evaluable, but the
possibility ofcureof patients withlimited facialdisease using
therapywasconﬁrmed(63%survivalinpatientswithdisease
in the head only), and some patients with more extensive
diseasealsosurvived(33%survivalin21childrenwithtumor
involving the abdomen or other sites).
In 2000, a SIOP study was initiated in Malawi consisting
of a combination of cyclophosphamide (O), vincristine (V),
prednisone (P), and methotrexate (M) given as COP1,
COP2, COMP1, and COMP2 [47]. A total of 30 boys and
12 girls were entered in study, but 14 patients died during or
shortly after the initiation of therapy, and projected event-
free survival at one year is not promising, being 50% in
stage I and II, 33% in stage III, and 25% in stage IV (33%
overall). Although morbidity and mortality was high, only
300 mgs of cyclophosphamide was used, being increased
to 500 mgs in the COMP cycles. The authors felt that
the likeliest explanation for the poor results was the low
cumulative dose of cyclophosphamide. A small protocol
(40 patients) of higher-dose cyclophosphamide (40mgs per
M2), IT methotrexate, and hydrocortisone conducted in
Malawi in 2006 gave a result of approximately 48% survival
for an average cost of less than $50 [49]. The ability to
“rescue” patients with high-dose cyclophosphamide and
methotrexate [50], suggests that many of these patients, as
in the 1960s and 1970s, were undertreated.6 Advances in Hematology
A much larger study being conducted by the INCTR in
several equatorial African countries is in progress, and initial
results look promising. This protocol uses higher doses of
cyclophosphamide (1200mgs/m2) with vincristine and me-
thotrexate as the ﬁrst-line therapy, and has a salvage regimen
(second line), which has induced complete responses in
approximately a third of patients resistant to the ﬁrst-line
therapy. This approach, in which future higher risk patients
will receive both the ﬁrst- and second-line therapy (ritux-
imab remains a possibility but may have to be excluded be-
cause of cost), seems likely to produce very acceptable results
for equatorial Africa as it already has in India, Egypt, and the
USA, albeit with higher doses in the USA [40, 41, 51, 52].
In countries where resources are less limited, results are
better since more intensive therapy can be safely given to
patients with extensive disease; for example, somewhat
modiﬁed versions of the highly eﬀective French and German
protocols. Depending upon the level of development, results
approach those being achieved in high-income countries.
Sadly, therefore, one is forced to conclude that a large num-
ber of children in equatorial Africa still receive inadequate
therapy, and outside formal clinical trials, the advances made
30–40 years ago (for the most part) [53, 54]h a v el e dt oo n l y
limited gains, in the ensuing period in terms of the cure of
patients with African Burkitt lymphoma, largely because of
the major resource limitations and poor access to care.
4. Conclusions
African BL, discovered and initially investigated in equa-
torial Africa, has provided an important model for the
epidemiology, pathogenesis, and treatment of many other
lymphomas. In particular, the value of combination therapy
and intrathecal prophylaxis were strongly suggested in the
early clinical trials in African Burkitt lymphoma although
numbers were small. Collaboration between resource-rich
countries and African countries should both improve the
care of patients with BL in Africa, where treatment needs to
be intensiﬁed, and lessen the side eﬀects of therapy outside
Africa, where treatment is probably still more intensive than
it need be. The use of newer agents such as rituximab may
prove to be prohibitively expensive for the time being but
is likely eventually to be introduced into the treatment of
African patients for reasons of lower toxicity and, eventually,
overall lower cost (the treatment of toxic complications can
be costly).
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